CareerExamPro

RAPS RAC-Devices, RAC-Drugs & Clinical Trials (GCP) practice questions

20 questions from the RAPS RAC, ACRP/SOCRA, MPJE & ASQ CQE practice test.

Start practising

RAPS RAC-Devices, RAC-Drugs & Clinical Trials (GCP) practice drill

10 realistic exam questions, graded as you go, with the exact rule or statute citation for every answer. Start free, no sign-up.

Sample questions

A medical device manufacturer develops a novel noninvasive optical sensor designed to screen for peripheral arterial disease in outpatient clinics. A thorough search of FDA databases confirms that no legally marketed predicate device exists, yet the company's risk analysis indicates that general and special controls will provide reasonable assurance of safety and effectiveness. Which FDA premarket submission pathway is most appropriate?

  1. A Traditional 510(k) citing a Class II pulse oximeter as a split predicate and proposing bench testing for the new intended use.
  2. A Premarket Approval (PMA) application, because every novel device without a predicate must complete Class III clinical review.
  3. A De Novo classification request to create a new Class I or Class II device type usable as a predicate.
  4. A Humanitarian Device Exemption (HDE), because lacking a legally marketed predicate exempts the sensor from effectiveness evidence.
Show the answer

C. A De Novo classification request to create a new Class I or Class II device type usable as a predicate.

Under FDCA Section 513(f)(2) and 21 CFR Part 860 Subpart D, novel devices lacking a legally marketed predicate are automatically classified into Class III by statute, but low-to-moderate risk devices for which general controls alone (Class I) or general and special controls (Class II) provide reasonable assurance of safety and effectiveness may use the De Novo classification pathway. A granted De Novo creates a new classification regulation and allows the device to serve as a predicate for future 510(k) submissions. Split predicates with different intended uses are not permitted under 510(k), and HDE requires a rare disease/condition affecting fewer than 8,000 individuals per year in the US.

Reference: FDCA § 513(f)(2) / 21 CFR Part 860 Subpart D (De Novo Classification Process)

On Monday morning, a Class II infusion pump manufacturer becomes aware of a firmware defect across an entire distributed lot that causes unintended rapid bolus delivery, requiring immediate remedial action to prevent an unreasonable risk of substantial harm to the public health. No deaths have been reported yet. Under 21 CFR Part 803 (Medical Device Reporting), what is the mandatory FDA reporting timeline?

  1. Submit an electronic MDR within 30 calendar days, because 5-day reporting applies only after a confirmed fatality.
  2. Submit an electronic 5-day MDR to FDA no later than 5 work days after becoming aware that remedial action is necessary.
  3. Submit a written safety report within 15 calendar days under the expedited timeline governing IND drug applications.
  4. Submit an annual summary MDR report at fiscal year-end, provided a field safety notice is sent to hospitals within 10 business days.
Show the answer

B. Submit an electronic 5-day MDR to FDA no later than 5 work days after becoming aware that remedial action is necessary.

Under 21 CFR 803.53(a), a device manufacturer must submit a 5-day Medical Device Report (MDR) to FDA no later than 5 work days after becoming aware that a reportable event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health (or after receiving a written FDA request for a 5-day report). Standard death, serious injury, and reportable malfunction MDRs that do not require immediate remedial action are due within 30 calendar days under 21 CFR 803.50.

Reference: 21 CFR 803.50 & 21 CFR 803.53 (FDA Medical Device Reporting Timelines)

A medical device manufacturer discovers that a packaging seal defect on a single lot of sterile implantable cardiac leads compromises sterility and creates a reasonable probability of life-threatening endocarditis or death if implanted. The firm initiates a voluntary field removal. How will FDA classify this recall under 21 CFR Part 7, and what Part 806 reporting obligation applies?

  1. Class II recall because the defect affects sterile packaging rather than electrical performance, with no Part 806 report needed.
  2. Class III recall because the firm initiated the removal voluntarily before an FDA order, requiring only an internal CAPA log entry.
  3. Class I recall, with a written 21 CFR 806 report submitted to FDA within 10 working days of initiating the field removal.
  4. Market withdrawal rather than a recall because no patients have developed infection yet, requiring FDA notice within 30 calendar days.
Show the answer

C. Class I recall, with a written 21 CFR 806 report submitted to FDA within 10 working days of initiating the field removal.

Under 21 CFR 7.3(m), a Class I recall applies when there is a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death—a compromised sterile barrier on an implantable cardiac lead clearly meets this threshold. Additionally, under 21 CFR 806.10, a device manufacturer must submit a written report to FDA within 10 working days of initiating any correction or removal conducted to reduce a risk to health posed by the device (unless the same event was already reported under Part 803).

Reference: 21 CFR 7.3(m) (Recall Classification) & 21 CFR 806.10 (Corrections and Removals)

Other topics